Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm to use 2016/17 R&D tax rebate for Abscopal Effect research and Brain Cancer project

• $855K received for inaugural year of operation

• Funds to boost key R&D projects in brain cancer and abscopal response

Sydney, 17 January 2018: Noxopharm (NOX:ASX) is pleased to announce that it has received $855,518 under the Federal Government’s Research and Development (R&D) Tax Incentive Scheme. This amount pertains to expenditure in the 2016/2017 financial year and follows the Company’s listing on the ASX in August 2016.

Noxopharm CEO, Graham Kelly, explained that the funds have been earmarked for two key company R&D initiatives: (i) the brain cancer project, and (ii) an abscopal response project.

For further information please download PDF attached:
Download this document